Efavirenz-Tenofovir DF-Emtricitabine (Atripla)

Prepared by:
David H. Spach, MD
Brian R. Wood, MD

Last Updated: December 28, 2022
Efavirenz-Tenofovir DF-Emtricitabine

Dose: 1 tablet once daily on an empty stomach
Efavirenz-Tenofovir DF-Emtricitabine

- **Atripla Components:**
  - Efavirenz 600mg
  - Tenofovir disoproxil fumarate: 300 mg
  - Emtricitabine: 200 mg

- **Dosing:**
  - 1 tablet daily on empty stomach (bedtime dosing recommended to minimize side effects)

- **Pregnancy**
  - May cause fetal harm when administered during the first trimester of pregnancy

- **Common Adverse Events (≥10%)**
  - Nausea, diarrhea, headache, dizziness, depression, insomnia, abnormal dreams, rash

Source: Efavirenz-Tenofovir DF-Emtricitabine. Prescribing Information.
Efavirenz-Tenofovir DF-Emtricitabine
Summary of Key Phase 3 Studies

• Trials in Treatment Naïve
  – ASSERT: ABC-3TC + EFV versus TDF-FTC plus EFV
  – STUDY 934: TDF + FTC + EFV versus ZDV-3TC + EFV
  – STARTMRK: RAL + TDF- FTC versus EFV + TDF-FTC
  – ECHO: RPV + FTC-TDF versus EFV + FTC-TDF
  – STaR: RPV-FTC-TDF versus EFV-TDF-FTC
  – SINGLE: DTG + ABC-3TC versus EFV-TDF-FTC
  – STUDY 102: EVG-COBI-FTC-TDF versus EFV-TDF-FTC

• Switch Trials
  – Study 115 SWEET: Switch from EFV + AZT-3TC to EFV + TDF-FDC
  – STUDY 073: Simplification to EFV-FTC-TDF
Efavirenz-Tenofovir DF-Emtricitabine

Trials in Treatment Treatment-Naïve Adults
EFV + ABC-3TC versus EFV + TDF-FTC

ASSERT Trial
Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC

ASSERT: Study Design

• **Background**: Randomized, open label, phase 3 study comparing tenofovir DF-emtricitabine plus efavirenz with zidovudine-lamivudine plus efavirenz in antiretroviral-naïve adults with HIV

• **Inclusion Criteria (n = 385)**
  - Antiretroviral-naïve adults
  - Age ≥18 years
  - HIV RNA ≥1,000 copies/mL
  - HLA-B*5701 negative
  - CrCl ≥50 mL/min
  - No AIDS-defining condition or HBV infection

• **Treatment Arms**
  - Efavirenz + abacavir-lamivudine
  - Efavirenz + tenofovir DF-emtricitabine

Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC
ASSERT: Results

Week 48 Virologic Response (Intent-to-Treat Analysis)

Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC
ASSERT: Renal Biomarkers

Week 48: Changes in Markers of Renal Tubular Function from Baseline

Interpretation: “The study showed no difference in estimated glomerular filtration rate between the arms, however, increases in markers of tubular dysfunction were observed in the tenofovir/emtricitabine arm, the long-term consequence of which is unclear. A significant difference in efficacy favoring tenofovir/emtricitabine was observed.”

Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC
ASSERT: Bone Effects

Week 48: Changes in Spine and Hip Bone Mineral Density from Baseline

Efavirenz + ABC-3TC versus Efavirenz + TDF-FTC

ASSERT: Bone Effects

Week 48: Proportion of Subjects with Decrease in BMD from Baseline

EFV + TDF + FTC versus EFV + ZDV-3TC

Study 934
Efavirenz + TDF + FTC + versus Efavirenz + ZDV-3TC
Study 934: Study Design

- **Background**: Randomized, open label phase 3 study comparing efavirenz plus either tenofovir DF and emtricitabine or fixed-dose zidovudine-lamivudine

- **Inclusion Criteria (n = 509)**
  - Antiretroviral-naïve adults
  - Age ≥18 years
  - HIV RNA ≥10,000 copies/mL
  - CD4 >50 cells/mm³
  - No AIDS conditions in prior 30 days

- **Treatment Arms**
  - Efavirenz + tenofovir DF + emtricitabine
  - Efavirenz + zidovudine-lamivudine

Efavirenz + TDF + FTC + versus Efavirenz + ZDV-3TC
Study 934: Results

Week 48: Virologic Response (<400 copies/mL)

<table>
<thead>
<tr>
<th>Study Populations</th>
<th>HIV RNA &lt;400 copies/mL (%)</th>
<th>ITT Population</th>
<th>Excluding NNRTI-R</th>
</tr>
</thead>
<tbody>
<tr>
<td>EFV + TDF + FTC</td>
<td>81</td>
<td>206/255</td>
<td>206/244</td>
</tr>
<tr>
<td>EFV + ZDV-3TC</td>
<td>70</td>
<td>177/254</td>
<td>177/243</td>
</tr>
</tbody>
</table>

Abbreviations: ITT = Intention-to-Treat; NNRTI-R = Patients with baseline NNRTI mutations.

Efavirenz + TDF + FTC + versus Efavirenz + ZDV-3TC

Study 934: Results

Week 48: Virologic Response (<50 copies/mL)


Abbreviations: ITT = Intention-to-Treat; NNRTI-R = Patients with baseline NNRTI resistance mutations.
Efavirenz + TDF + FTC + versus Efavirenz + ZDV-3TC  
Study 934: Results

Week 48: Immunologic Response

Efavirenz + TDF + FTC + versus Efavirenz + ZDV-3TC
Study 934: Results

Adverse Events Through 48 Weeks

Efavirenz + TDF + FTC + versus Efavirenz + ZDV-3TC  
Study 934: Common Adverse Events

<table>
<thead>
<tr>
<th>Treatment Emergent Adverse Events in ≥ 5% of Subjects in Either Arm</th>
<th>EFV + TDF + FTC (n = 257)</th>
<th>EFV + ZVD-3TC (n= 254)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness</td>
<td>8%</td>
<td>7%</td>
</tr>
<tr>
<td>Nausea</td>
<td>8%</td>
<td>6%</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>7%</td>
<td>6%</td>
</tr>
<tr>
<td>Depression</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td>Headache</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Rash</td>
<td>5%</td>
<td>4%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>4%</td>
<td>5%</td>
</tr>
<tr>
<td>Anemia</td>
<td>&lt;1%</td>
<td>5%</td>
</tr>
</tbody>
</table>

Interpretation: “Through week 48, the combination of tenofovir DF and emtricitabine plus efavirenz fulfilled the criteria for noninferiority to a fixed dose of zidovudine and lamivudine plus efavirenz and proved superior in terms of virologic suppression, CD4 response, and adverse events resulting in discontinuation of the study drugs.”

Raltegravir + TDF-FTC versus Efavirenz + TDF-FTC

STARTMRK Trial
**Background:** Randomized, double-blind, phase 3 study comparing the safety and efficacy of raltegravir versus efavirenz, each in combination with tenofovir DF and emtricitabine

**Inclusion Criteria (n = 569)**
- Antiretroviral-naïve patients
- Age ≥18 years
- HIV RNA ≥5000 copies/mL
- No resistance to EFV, TDF, or FTC

**Treatment Arms**
- Raltegravir + TDF-FTC
- Efavirenz + TDF-FTC

Raltegravir + TDF-FTC versus Efavirenz + TDF-FTC

STARTMRK: Results

Week 48: Virologic Response (Primary Analysis, Missing=Failure)


HIV RNA <50 copies/mL (%)

- Raltegravir + TDF-FTC: 86% (241/281)
- Efavirenz + TDF-FTC: 82% (230/282)
Raltegravir + TDF-FTC versus Efavirenz + TDF-FTC
STARTMRK: Results

Week 48 Virologic Response (Observed-Failure Method)

Raltegravir + TDF-FTC versus Efavirenz + TDF-FTC
STARTMRK: Results

Week 48 Virologic Response

Raltegravir + TDF-FTC versus Efavirenz + TDF-FTC
STARTMRK: Results

Adverse Events through 48 Weeks

### Raltegravir + TDF-FTC versus Efavirenz + TDF-FTC

**STARTMRK: Results**

**Week 48: Changes in Lipid Concentrations from Baseline**

<table>
<thead>
<tr>
<th>Component</th>
<th>Raltegravir + TDF-FTC</th>
<th>Efavirenz + TDF-FTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol</td>
<td>0.55</td>
<td>1.82</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>2.08</td>
<td>-0.16</td>
</tr>
<tr>
<td>HDL</td>
<td>0.23</td>
<td>0.56</td>
</tr>
<tr>
<td>LDL</td>
<td>0.33</td>
<td>0.89</td>
</tr>
</tbody>
</table>

### Treatment Emergent Adverse Events in >10% of Subjects in Either Arm

<table>
<thead>
<tr>
<th>Event</th>
<th>RAL + TDF-FTC (n = 281)</th>
<th>EFV + TDF-FTC (n = 282)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness</td>
<td>6%</td>
<td>34%</td>
</tr>
<tr>
<td>Headache</td>
<td>9%</td>
<td>14%</td>
</tr>
<tr>
<td>Abnormal dreams</td>
<td>7%</td>
<td>13%</td>
</tr>
<tr>
<td>Immune Reconstitution Inflammatory Syndrome</td>
<td>6%</td>
<td>4%</td>
</tr>
</tbody>
</table>

Interpretation: “Raltegravir-based combination treatment had rapid and potent antiretroviral activity, which was non-inferior to that of efavirenz at week 48. Raltegravir is a well tolerated alternative to efavirenz as part of a combination regimen against HIV-1 in treatment-naive patients.”

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO Trial
Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC
ECHO: Study Design

- **Background**: Randomized, double-blind, phase 3 trial comparing rilpivirine and efavirenz in combination with a fixed background regimen consisting of tenofovir DF-emtricitabine in treatment-naïve adults with HIV

- **Inclusion Criteria (n = 690)**
  - Antiretroviral-naïve adults
  - Age ≥18 years
  - HIV RNA ≥5,000 copies/mL
  - No resistance to any study drugs

- **Treatment Arms**
  - Rilpivirine + Tenofovir DF-Emtricitabine
  - Efavirenz + Tenofovir DF-Emtricitabine

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC
ECHO: Results

48 Week Virologic Response (Intention-to-Treat)

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

**ECHO: Results**

48 Week Virologic Failure and Discontinuations (Intention-to-Treat)

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC
ECHO: Resistance Results

Incidence of NNRTI Resistance Associated Mutations (RAMs)

The percentages represent the number of participants who developed each specific NNRTI RAM out of the number of participants who developed any NNRTI RAM in that arm of the trial (the n listed at the top of the graph).

Rilpivirine + TDF-FTC versus Efavirenz + TDF-FTC

ECHO: Resistance Results

Incidence of NRTI Resistance Associated Mutations (RAMs)

The percentages represent the number of participants who developed each specific NRTI RAM out of the number of participants who developed any NRTI RAM in that arm of the trial (the n listed at the top of the graph).

**Interpretation**: “Rilpivirine showed non-inferior efficacy compared with efavirenz, with a higher virological-failure rate, but a more favourable safety and tolerability profile.”

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC

STaR Trial
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC
STaR Study: Design

- **Background**: Randomized, open-label, phase 3b trial comparing safety and efficacy of two single-tablet regimens, RPV-TDF-FTC and EFV-TDF-FTC, in treatment-naïve adults with HIV

- **Inclusion Criteria (n = 786)**
  - Antiretroviral-naïve adults
  - Age ≥18 years
  - HIV RNA ≥2,500 copies/mL
  - No resistance to EFV, RPV, TDF, or FTC

- **Treatment Arms**
  - Rilpivirine-tenofovir DF-emtricitabine
  - Efavirenz-tenofovir DF-emtricitabine

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC
STaR: Results

Week 48 Virologic Response (Intent-to-Treat Analysis)

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC
STaR: Results

48 Week Virologic Outcomes

## Treatment Emergent Adverse Events in > 5% of Subjects in Either Arm

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>RPV-TDF-FTC (n = 392)</th>
<th>EFV-TDF-FTC (n = 394)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dizziness</td>
<td>6.6%</td>
<td>22.2%</td>
</tr>
<tr>
<td>Insomnia</td>
<td>9.6%</td>
<td>14.0%</td>
</tr>
<tr>
<td>Somnolence</td>
<td>2.5%</td>
<td>6.9%</td>
</tr>
<tr>
<td>Headache</td>
<td>12.4%</td>
<td>13.5%</td>
</tr>
<tr>
<td>Abnormal Dreams</td>
<td>5.8%</td>
<td>24.5%</td>
</tr>
<tr>
<td>Depression</td>
<td>6.6%</td>
<td>8.9%</td>
</tr>
<tr>
<td>Anxiety</td>
<td>5.1%</td>
<td>8.4%</td>
</tr>
<tr>
<td>Folliculitis</td>
<td>5.3%</td>
<td>1.0%</td>
</tr>
<tr>
<td>Rash</td>
<td>6.1%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>

Conclusion: “In treatment-naïve participants, RPV/FTC/TDF demonstrated noninferior efficacy and improved tolerability compared with EFV/FTC/TDF, as well as a statistically significant difference in efficacy for participants with baseline HIV-1 RNA 100,000 copies/mL or less at week 48.”
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC

STaR Trial: Week 96 Resistance Data
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC
STaR Resistance Analysis: Result

Development of Genotypic Resistance at Week 48

Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC
STaR Resistance Analysis: Result

Development of Resistance to Study Drugs at 48 weeks, by Viral Load

<table>
<thead>
<tr>
<th>Baseline HIV RNA</th>
<th>RPV-TDF-FTC</th>
<th>EFV-TDF-FTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>4.3</td>
<td>0.8</td>
</tr>
<tr>
<td>≤100,000 copies/mL</td>
<td>1.9</td>
<td>0.8</td>
</tr>
<tr>
<td>&gt;100,000 copies/mL</td>
<td>9.0</td>
<td>0.7</td>
</tr>
</tbody>
</table>

Conclusions: “Among subjects in the primary resistance-associated populations (RAP), resistance development to RPV/FTC/TDF consisted of NNRTI and NRTI mutations and was more frequent than resistance development to EFV/FTC/TDF. In subjects with baseline viral load \( \leq 100,000 \) copies/mL, resistance development was low (<2%) for both RPV/FTC/TDF and EFV/FTC/TDF arms and less frequent compared with subjects with baseline viral load >100,000 copies/mL, for RPV/FTC/TDF.”
Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study
Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Design

• **Background**: Randomized, double-blind study, phase 3 trial comparing dolutegravir + abacavir-lamivudine with efavirenz-tenofovir DF-emtricitabine

• **Inclusion Criteria** (n = 833)
  - Antiretroviral-naïve adults
  - Age ≥18 years
  - HIV RNA ≥1,000 copies/mL
  - No active CDC AIDS-defining condition

• **Treatment Arms**
  - Dolutegravir (QD) + Abacavir-Lamivudine
  - Efavirenz-Tenofovir DF-Emtricitabine

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Results

Week 48 Virologic Response (Intention-to-Treat Analysis)

HIV RNA <50 copies/mL (%)

<table>
<thead>
<tr>
<th>Baseline HIV RNA</th>
<th>Dolutegravir + ABC-3TC</th>
<th>Efavirenz-TDF-FTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>88/414</td>
<td>338/419</td>
</tr>
<tr>
<td>≤100,000 copies/mL</td>
<td>90/280</td>
<td>238/288</td>
</tr>
<tr>
<td>&gt;100,000 copies/mL</td>
<td>83/134</td>
<td>100/131</td>
</tr>
</tbody>
</table>

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Results

Week 48 Virologic Response (Intention-to-Treat Analysis)

![Bar chart showing virologic response and discontinuation rates for Dolutegravir + ABC-3TC and Efavirenz-TDF-FTC groups at Week 48.]

**HIV RNA <50 copies/mL (%)**

- **Dolutegravir + ABC-3TC**:
  - All: 88%
  - ≤100,000 copies/mL: 90%
  - >100,000 copies/mL: 83%

- **Efavirenz-TDF-FTC**:
  - All: 83%
  - ≤100,000 copies/mL: 83%
  - >100,000 copies/mL: 76%

**Discontinuation of therapy due to adverse events**

- Dolutegravir + Abacavir-Lamivudine: 2%
- Efavirenz-Tenofovir-Emtricitabine: 10%

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Results

Mean Change from Baseline in Serum Creatinine Levels

© 2013 Massachusetts Medical Society. Reprinted with permission from Massachusetts Medical Society.
Conclusions: “Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine.”

Dolutegravir + ABC-3TC versus Efavirenz-TDF-FTC
SINGLE Study: Results

Week 96 and Week 144 Virologic Response (Intention-to-Treat Analysis)

## Treatment-Emergent Adverse Events (AEs >5%)

<table>
<thead>
<tr>
<th></th>
<th>DTG-ABC-3TC (n = 414)</th>
<th>EFV-TDF-FTC (n = 419)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Week 96</td>
<td>Week 144</td>
</tr>
<tr>
<td>Any, %</td>
<td>44</td>
<td>+1</td>
</tr>
<tr>
<td>Dizziness, %</td>
<td>7</td>
<td>+0</td>
</tr>
<tr>
<td>Abnormal dreams, %</td>
<td>7</td>
<td>+0</td>
</tr>
<tr>
<td>Nausea, %</td>
<td>11</td>
<td>+0.2</td>
</tr>
<tr>
<td>Insomnia, %</td>
<td>10</td>
<td>+0</td>
</tr>
<tr>
<td>Diarrhea, %</td>
<td>6</td>
<td>+0</td>
</tr>
<tr>
<td>Fatigue, %</td>
<td>7</td>
<td>+0</td>
</tr>
<tr>
<td>Headache, %</td>
<td>6</td>
<td>+0</td>
</tr>
<tr>
<td>Rash, %</td>
<td>&lt;1</td>
<td>+0</td>
</tr>
</tbody>
</table>

Elvitegravir-Cobicistat-TDF-FTC versus Efavirenz-TDF-FTC

Study 102
Elvitegravir-Cobicistat-TDF-FTC versus Efavirenz-TDF-FTC
Study 102: Design

• **Background**: Randomized, double-blind, phase 3 trial comparing elvitegravir-cobicistat-tenofovir DF-emtricitabine with efavirenz-tenofovir DF-emtricitabine

• **Inclusion Criteria** (n = 700)
  - Antiretroviral-naïve adults
  - Age ≥18 years
  - HIV RNA ≥5,000 copies/mL
  - No AIDS conditions in previous 30 days

• **Treatment Arms**
  - Elvitegravir-Cobicistat-TDF-FTC
  - Efavirenz-TDF-FTC

Elvitegravir-Cobicistat-TDF-FTC versus Efavirenz-TDF-FTC
Study 102: Results

Week 48 Virologic Response

<table>
<thead>
<tr>
<th>Baseline HIV RNA</th>
<th>Elvitegravir-Cobicistat-TDF-FTC</th>
<th>Efavirenz-TDF-FTC</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>88/305 to 348</td>
<td>84/296 to 352</td>
</tr>
<tr>
<td>≤100,000 copies/mL</td>
<td>90/207 to 230</td>
<td>85/201 to 236</td>
</tr>
<tr>
<td>&gt;100,000 copies/mL</td>
<td>84/99 to 118</td>
<td>82/95 to 116</td>
</tr>
</tbody>
</table>

## Elvitegravir-Cobicistat-TDF-FTC versus Efavirenz-TDF-FTC

### Study 102: Common Adverse Events

<table>
<thead>
<tr>
<th>Treatment-Emergent Adverse Events in ≥ 10% of Subjects in Either Group</th>
<th>EVG-COBI-TDF-FTC (n = 348)</th>
<th>EFV-TDF-FTC (n= 352)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>23%</td>
<td>19%</td>
</tr>
<tr>
<td>Nausea*</td>
<td>21%</td>
<td>14%</td>
</tr>
<tr>
<td>Fatigue</td>
<td>11%</td>
<td>13%</td>
</tr>
<tr>
<td>Upper Respiratory Tract Infection</td>
<td>14%</td>
<td>11%</td>
</tr>
<tr>
<td>Dizziness^</td>
<td>7%</td>
<td>24%</td>
</tr>
<tr>
<td>Headache</td>
<td>14%</td>
<td>10%</td>
</tr>
<tr>
<td>Abnormal Dreams^</td>
<td>15%</td>
<td>27%</td>
</tr>
<tr>
<td>Insomnia†</td>
<td>9%</td>
<td>14%</td>
</tr>
<tr>
<td>Depression</td>
<td>9%</td>
<td>11%</td>
</tr>
<tr>
<td>Rash §</td>
<td>6%</td>
<td>12%</td>
</tr>
</tbody>
</table>

*p < 0.016; ^p < 0.001; †p < 0.031; § p = 0.009

Elvitegravir-Cobicistat-TDF-FTC versus Efavirenz-TDF-FTC
Study 102: Conclusions

**Interpretation:** “This study met the primary endpoint of non-inferiority of elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/TDF/FTC) to efavirenz/emtricitabine/tenofovir (EFV/TDF/FTC) and demonstrates the robust antiviral efficacy of the only integrase inhibitor-based single tablet regimen for initial HIV treatment, irrespective of viral load.”

Efavirenz-Tenofovir DF-Emtricitabine

Switch Studies
Switch from Efavirenz + ZDV-3TC to Efavirenz + TDF-FTC

SWEET Trial
Switch to Efavirenz + TDF-FTC
SWEET: Study Design

- **Background**: Randomized, controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed on efavirenz-based ART by switching from twice-daily zidovudine-lamivudine to once-daily tenofovir DF-emtricitabine in adults with HIV.

- **Inclusion Criteria (n = 234)**
  - Age ≥18 years
  - On EFV + ZDV-3TC for >6 months
  - No resistance to study drugs
  - HIV RNA <400 copies/mL for ≥3 months and HIV RNA <50 copies/mL on 2 occasions

- **Treatment Arms**
  - Efavirenz + TDF-FTC
  - Efavirenz + ZDV-3TC

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 48 Virologic Response (Intention-to-Treat Analysis, Missing=Failure)

Switch to Efavirenz + TDF-FTC  
SWEET: Results  

Week 48: Patients with Change in Absolute Hemoglobin from Baseline

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 24: Change in Limb Fat from Baseline

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 24: Change in Plasma Lipids from Baseline

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Change in Median Value (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol</td>
<td>-0.39  -0.06</td>
</tr>
<tr>
<td>HDL</td>
<td>-0.03  -0.02</td>
</tr>
<tr>
<td>LDL</td>
<td>-0.10  -0.09</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>-0.24  0.05</td>
</tr>
</tbody>
</table>

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 24: Change in Plasma Lipids, by Baseline Cholesterol

Switch to Efavirenz + TDF-FTC
SWEET: Results

Week 48: Change in Plasma Lipids from Baseline

<table>
<thead>
<tr>
<th>Lipid</th>
<th>Median Change in Plasma Lipids (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Cholesterol</td>
<td>-0.22</td>
</tr>
<tr>
<td>HDL</td>
<td>0.04</td>
</tr>
<tr>
<td>LDL</td>
<td>-0.08</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>-0.14</td>
</tr>
</tbody>
</table>

**Interpretation:** “Switching from zidovudine/lamivudine to tenofovir disoproxil fumarate/emtricitabine in persons on efavirenz therapy maintains virological control, establishes a once-daily regimen, results in improvements in hemoglobin and key lipid parameters, and preserves and restores limb fat relative to continuation of zidovudine/lamivudine.”

Simplification to Efavirenz-TDF-FTC

STUDY 073
Simplification to Efavirenz-TDF-FTC Study 073: Study Design

**Background:** Randomized, controlled, open-label, phase 3 trial evaluating a simplification strategy for patients suppressed on baseline ART by switching to a single-tablet regimen of efavirenz-tenofovir DF-emtricitabine once daily

**Inclusion Criteria (n = 300)**
- Age ≥18 years
- HIV RNA ≤200 copies/mL for ≥3 months
- No new AIDS-defining conditions in past 30 days
- On 1st ART regimen or viral suppression on previous protease inhibitor-based therapy at time of prior therapy switch

**Treatment Arms**
- Switch arm: Efavirenz-tenofovir DF-emtricitabine
- Stay arm: maintain baseline ART

---

Simplification to Efavirenz-TDF-FTC
Study 073: Results

Week 48 Virologic Response by RNA Threshold

Simplification to Efavirenz-TDF-FTC
Study 073: Subgroup Analysis Result

Week 48 Virologic Response, by Baseline Regimen (Intent-to-Treat, Noncompletion = Failure)

Interpretation: “Simplification to EFV/FTC/TDF maintained high and comparable rates of virologic suppression versus stay on baseline regimen (SBR) through 48 weeks.”

Acknowledgments

The National HIV Curriculum is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling $1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington’s Infectious Diseases Education and Assessment (IDEA) Program.